Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.52 |
| ▸ | PGK2 | P07205 | 1/20 | 0.52 |
| ▸ | PGD | P52209 | 3/20 | 0.48 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | SGPL1 | O95470 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340890 | 1.00 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL2475126 | 1.00 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL1286423 | 0.87 | PGK1 (0.58) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL3950043 | 0.80 | LPAR5 (0.61) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL6655023 | 0.80 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL24706048 | 0.80 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL7340 | 0.80 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL12282272 | 0.80 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL14278848 | 0.80 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL14278847 | 0.80 | PGK1 (0.52) | PGK1PGK2PGDMPILPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | PGK1 1485/4885PGK2 2016/4885PGD 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.